A Phase II Evaluation of Enzastaurin in the Treatment of Persistent or Recurrent Ovarian or Primary Peritoneal Carcinoma.
Phase of Trial: Phase II
Latest Information Update: 02 Apr 2015
At a glance
- Drugs Enzastaurin (Primary)
- Indications Ovarian cancer; Peritoneal cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Eli Lilly
- 10 Mar 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov (NCT00420381).
- 26 Jun 2014 Planned End Date changed from 1 Jun 2014 to 1 Jan 2015 as reported by ClinicalTrials.gov (NCT00420381).
- 06 May 2014 Planned end date changed from 1 Jan 2014 to 1 Jun 2014 as reported by ClinicalTrials.gov.